Sharemaestro Newsreel

Zoetis (ZTS) Is Down 5.8% After Cutting 2026 Outlook And Overhauling Leadership Structure

Empowered Funds LLC Takes Position in Lantheus Holdings, Inc. $LNTH

Empowered Funds LLC initiated a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by purchasing 11,979 shares valued at approximately $909,000. This comes as Lantheus exceeded quarterly earnings expectations, reporting $1.55 EPS against a $1.30 consensus, though analyst sentiment has softened with several downgrades to …

US Stock Market Today: S&P 500 Futures Climb On Softer Jobs Data And Yields

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The Morning Bull - US Market Morning Update Monday, Aug, 10 2026 US stock futures are pointing higher this morning, with the S&P …

California State Teachers Retirement System Has $2.73 Million Stock Holdings in Liquidia Corporation $LQDA

The California State Teachers Retirement System increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 25% to 72,438 shares, now valued at approximately $2.73 million. Institutional investors collectively own 64.54% of the company, which has received a consensus "Moderate Buy" rating from analysts with an …

Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates

SCYNEXIS (SCYX) Earnings Date and Reports 2026

Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Indivior PLC (INDV), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 5 analysts, the stock has a "Buy" trend with a target price of $49.000, suggesting a 27.37% upside. The report …

Dr. Reddy's Laboratories falls Monday, underperforms market

Shares of Dr. Reddy's Laboratories Ltd. fell by 1.25% on Monday, underperforming the broader market despite a favorable trading session where the BSE SENSEX Index rose. The company's stock closed at 1,157.35 Indian rupees, which is 18.17% below its 52-week high reached on June …

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?

HC Wainwright Has Bearish Forecast for AMLX FY2029 Earnings

HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings

HC Wainwright has revised its FY2026 earnings estimate for Akebia Therapeutics (NASDAQ:AKBA) to a loss of $0.12 per share, down from a previous estimate of $0.08, while maintaining a "Buy" rating. Despite this negative revision, Akebia recently exceeded expectations in its latest quarterly results, …

Results: Amphastar Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

This article provides an analysis of Amphastar Pharmaceuticals, Inc.'s recent financial performance, highlighting that the company exceeded consensus expectations. It is anticipated that analysts will update their estimates based on these strong results. The piece will likely delve into the specific financial metrics that …

SIGA Technologies Inc (SIGA) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for SIGA Technologies Inc (SIGA), detailing estimated future EPS, revenue, net

Trading Systems Reacting to (EOLS) Volatility

This article analyzes Evolus Inc. (NASDAQ: EOLS) using AI models to generate trading strategies. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying compelling upside potential as no resistance levels remain above the current price. The analysis provides specific entry, …

Licensable picture: Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber speaks at an opening ceremony for its new headquarters in Tokyo

This article features a licensable picture of Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber. He is shown speaking at the opening ceremony for the company's new headquarters in Tokyo, Japan, on July 2, 2018. The image is credited to REUTERS/Kim Kyung-Hoon.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) who bought securities prior to June 16, 2025, and still hold them. The investigation aims to determine if Aquestive officers engaged in corporate wrongdoing. The firm …

ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance

ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance Animal health company Zoetis (NYSE:ZTS) fell short of the market's revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company's full-year revenue guidance of $9.22 billion at …

Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN)

Perrigo Company PLC (PRGO) Stock News Today

This article provides current stock news for Perrigo Company PLC (PRGO), including its latest market performance with a 2.31% gain and a market cap of $1.78 billion. The page details an overview of the company's financial information, stock score, and analyst ratings. It indicates …

COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance

Collegium Pharmaceutical (COLL) missed Q2 CY2026 revenue expectations but beat non-GAAP profit estimates, with sales increasing 6.3% year-on-year. The company's revenue guidance for the full year was lifted, primarily due to strong performance in its ADHD business, particularly Jornay PM and the integration of …

Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program

In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. …

Trulieve Cannabis: First NYSE-Listed Cannabis Stock Is A Buy (NYSE:TRLV)

Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV

Hennion & Walsh Asset Management Inc. has acquired a new stake in Indivior PLC (NASDAQ:INDV) worth approximately $14.78 million, representing 0.30% of the company. Institutional investors collectively own 60.33% of Indivior, which currently holds a "Moderate Buy" consensus rating with an average price target …

RGC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit, filed on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, alleges the company made materially …

Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Rating of "Moderate Buy" by Brokerages

Haleon PLC Sponsored ADR (NYSE:HLN) has received a consensus "Moderate Buy" rating from ten brokerages. While some firms upgraded the stock, others downgraded or maintained neutral views. The company recently declared a quarterly dividend of $0.0642 per share, and institutional investors have significantly modified …

Organogenesis Holdings (ORGO) After Earnings Cut, Guidance Reset And $75 Million Raise, Still A Bargain?

Alpha Teknova, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TKNO) 2026-08-09

Alpha Teknova, Inc. (TKNO) released its Q2 2026 earnings call presentation on August 9, 2026. The company reported an EPS of -$0.05, which beat estimates by $0.02, and revenue of $12.19M, beating expectations by $1.28M and showing an 18.45% year-over-year increase. The presentation is …

Does Elanco (ELAN) Have a Durable Edge in Animal Health After Its Screwworm EUA Win?

Elanco Animal Health (ELAN) reported stronger Q2 sales and net income, along with an FDA Emergency Use Authorization for its CLiK Extra screwworm-prevention spray. The company also raised its full-year revenue guidance, positioning it as a key player in addressing the New World screwworm …

Dimensional Fund Advisors LP Has $12.54 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Dimensional Fund Advisors LP significantly increased its stake in Amylyx Pharmaceuticals (NASDAQ:AMLX) by 17.1% in the first quarter, now holding 903,192 shares valued at $12.54 million. Despite institutional interest, Amylyx shares traded down 5.7% after opening and missed analysts' EPS estimates for the quarter. …

Cronos Group (TSX:CRON) Stock Can Profit Momentum Outrun Margin Doubts?

HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

RADNOR, Pa., Aug. 09, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who …

Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be …

OrganiGram Holdings Inc (OGI) Stock News Today

This article provides an overview of OrganiGram Holdings Inc (OGI) stock information, including its current price, market cap, and links to financial data, stock scores, and forecasts. It indicates that the news section for OGI is currently sparse, with more updates expected soon. The …

Eton Pharmaceuticals (ETON) Stock Could Be Pricey On A Very Large Three Year Run

Eton Pharmaceuticals (ETON) stock has seen significant long-term gains over the past three years but now appears expensive, passing only 2 of 6 valuation checks. The company trades at a P/S ratio of 14.6x, significantly higher than the industry average and its estimated fair …

Zoetis Q2 Earnings Call Highlights

Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand …

Collegium Pharmaceutical, Inc. Revenue Breakdown – NASDAQ:COLL

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) generated $780.57 million USD in revenue last year, primarily from its Pharmaceutical segment. This marks an increase from the previous year's $631.45 million USD, with the United States being the sole contributor to this revenue. The financial data highlights …